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 Good [morning/afternoon/evening]. Today I’d like to share with 
you what we’ve learned about Zika virus and pregnancy. 
 
 Today’s Zika outbreak is unprecedented. Although Zika was first 
identified almost 70 years ago, the potentially devastating 
effects on pregnancy are a recently recognized phenomenon. 
 Some of you here today may remember that the last time an 
infectious pathogen (rubella virus) caused an epidemic of 
congenital defects was more than 50 years ago, before an 
effective vaccine became available. 
 
 My goal today is to share the most current information 
available, but I encourage you to stay up-to-date as the science 
advances. Here’s a brief outline of my presentation. 
 
 First, let’s start with some basics. 
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 Zika is a single-stranded RNA virus that is closely related to 
dengue, yellow fever, Japanese encephalitis, and West Nile 
viruses.  
 It is primarily transmitted by the bite of two Aedes species 
mosquitoes, Aedes aegypti and Aedes albopictus.  
 Zika is also transmitted through several other routes including 
o Intrauterine and perinatal transmission  
o Sexual transmission 
o Laboratory exposure 
o And probably blood transfusion 
 
 
 As of December 29, 2016, 61 countries and territories 
worldwide are reporting active Zika virus transmission. Check 
the CDC website for the latest numbers and locations. 
 This map shows countries in which Zika virus is actively being 
transmitted by mosquitoes. Orange shading of a country doesn’t 
mean that Zika virus is being spread across the entire country; it 
just means that Zika virus being spread by local mosquitoes has 
been reported in at least one area of that country. Visit the CDC 
website for more specific information about where Zika virus is 
being locally transmitted. 
 To date, Florida and Texas have been the only states in the 
United States that have had local transmission. This occurred in 
small areas only in Miami-Dade County, FL and Brownsville, TX. 
 
 Now I would like to switch gears and talk about some of the 
clinical aspects of Zika. 
o Many people infected with Zika virus won’t have symptoms 
or will only have mild symptoms. 
o When symptoms do occur the most common ones are fever, 
rash, joint pain, and conjunctivitis (red eyes). 
o Symptoms typically last several days to a week. 
o  Severe disease requiring hospitalization has been 
uncommon and fatalities have been rarely reported.  
o Based on similar infections, once a person has been infected 
with Zika and cleared the virus from their blood, it is 
believed that he or she is likely to be protected from future 
infections. 
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 Although research is underway, there is currently no vaccine or 
specific antiviral treatment for Zika. 
o The cornerstone of treatment is supportive care. Patients 
should be advised to treat the symptoms, including  
o Rest 
o Drinking fluids to prevent dehydration and 
o Taking medicine such as acetaminophen to reduce fever 
and pain 
o Aspirin and NSAIDS should be avoided until dengue can 
be ruled out to reduce the risk of bleeding. Pregnant 
women should talk with their doctor before taking 
NSAIDS or aspirin. 
 
 When Zika virus is transmitted from a pregnant woman to her 
fetus, the effect on the health of the fetus and infant can be 
serious. We’ll focus now on Zika, Pregnancy, and Congenital Zika 
Syndrome. 
 
 
 Pregnant women can be infected with Zika through the same 
routes I discussed earlier, mainly  
o Through the bite of an infected mosquito or 
o Through sex without a condom with an infected partner 
 Zika may be passed to the fetus around the time of conception 
 If a women is infected during pregnancy, Zika can be passed to 
the fetus during pregnancy or around the time of birth. 
 
 The incidence of Zika virus infection in pregnant women is not 
known. 
 However, infection can occur in any trimester. 
 There is no evidence that pregnant women are more susceptible 
to Zika than non-pregnant women, and  
 The clinical course of Zika is similar for pregnant women and 
non-pregnant women  
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• Zika virus has been shown to be present in fetal tissue.  
• There is evidence of Zika virus detected in: 
o Amniotic fluid 
o Placenta  
o Fetal brain tissue 
o Products of conception  
• This image shows immunohistochemical staining of Zika virus 
antigen (red stain) in fetal brain tissue. This staining is present in 
the same areas where neuronal cell death/necrosis was 
identified by microscopic review of tissue morphology.   
• A CDC study released December 13, 2016, found that Zika virus 
can continue to replicate in infants' brains even after birth. This 
information could have important implications for babies born 
with microcephaly and for babies who are born seemingly 
healthy.  
• Zika virus has also been found in the placenta. 
 
 
 In April 2016, in an article published in the New England Journal 
of Medicine, scientists at CDC concluded that enough evidence 
had accumulated to determine Zika virus is a cause of 
microcephaly and other brain anomalies.   
 To reach this conclusion, the scientists conducted a systematic 
evaluation of the evidence, which supported a causal 
relationship between Zika virus infection and microcephaly and 
other serious brain anomalies. 
 
 
• Congenital Zika syndrome is now a recognized pattern of 
congenital anomalies associated with Zika virus infection during 
pregnancy that includes: 
o Severe microcephaly (small head size) resulting in a partially 
collapsed skull 
o Thin cerebral cortices with subcortical calcifications 
o Eye anomalies, including macular scarring and focal 
pigmentary retinal mottling 
o Congenital contractures or limited range of joint motion 
o Marked early hypertonia, or too much muscle tone, and 
symptoms of extrapyramidal involvement 
 A case series published in late November also demonstrated 
that microcephaly at birth is not a necessary feature of 
congenital Zika syndrome. Infants with head circumference in 
the normal range at birth can have brain abnormalities 
consistent with congenital Zika syndrome and can experience 
slowed head growth and develop microcephaly after birth.  
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• We don’t yet know the risk of microcephaly in infants of 
mothers infected with Zika virus during pregnancy, but we are 
learning more information.   
• Based on modeling data from the current outbreak in Brazil, the 
estimated risk of microcephaly was 1-13% when the infection 
occurred in the first trimester.  
• Currently, there are not enough data to estimate the risk when 
the infection occurs in the 2nd or 3rd trimester. 
• There are some limitations of this study, noted here, including 
that some pregnancies are ongoing, and microcephaly cases are 
still being reported and investigated. 
  
• A report from the US Zika Pregnancy Registry found that about 
6% of  women with laboratory evidence of possible recent Zika 
virus infection had birth defects potentially related to Zika virus.  
• The proportion of pregnancies with birth defects was similar 
(around 6%) among pregnant women who experienced 
symptoms and pregnant women who were asymptomatic.  
• This emphasizes the importance of screening pregnant women 
for Zika risk and testing them when indicated, because 
asymptomatic women are just as likely to have babies with birth 
defects.   
• The report also found that among women with maternal 
symptoms OR laboratory evidence of possible Zika virus 
infection in the first trimester of pregnancy, birth defects were 
reported in 11% of completed pregnancies.  
 
 
• Now, I will discuss CDC recommendations, first for 
preconception counseling.  
 
• CDC published updated interim guidance for preconception 
counseling and prevention of sexual transmission of Zika on 
September 30, 2016. 
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• This guidance includes recommendations to help healthcare 
providers discuss pregnancy planning with women and their 
partners after possible exposure to Zika. The table on this slide 
shows the suggested timeframes for waiting to get pregnant 
after possible exposure to Zika.  
• Women should wait at least 8 weeks after last possible exposure 
or symptom onset before attempting conception. Men should 
wait at least 6 months after last possible exposure or symptom 
onset The waiting period for men is longer because Zika virus 
can be found in semen longer than in other body fluids.  
 
• Preventing Zika infections during pregnancy is CDC’s top priority 
for the Zika response. This includes supporting women who 
want to delay or avoid pregnancy to avert Zika-related adverse 
pregnancy and birth outcomes. 
• Healthcare providers should discuss strategies to prevent 
unintended pregnancy among women who wish to avoid or 
delay pregnancy, including counseling on the use of the most 
effective contraceptive methods that meet couples’ lifestyle 
needs, and can be used correctly and consistently.  
• Additionally, healthcare providers should advise patients to 
consider using condoms correctly and consistently, in addition 
to other birth control methods, to reduce the risk of acquiring or 
transmitting Zika and other sexually transmitted infections. 
 
• Now, I will speak about the CDC’s guidance about testing for and 
diagnosing Zika virus infection. 
  
 
• In light of the adverse outcomes associated with Zika virus 
infection during pregnancy, all pregnant women should be 
assessed for Zika exposure, signs and symptoms at each 
prenatal visit. 
• They should be asked if they 
o Traveled to or live in an area with Zika or  
o Had sex without a condom with a partner with potential 
exposure to Zika.  
• CDC has developed a tool (shown here), which is available in 
both interactive and printable versions on CDC’s website, to 
help healthcare providers determine if testing is needed. 
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• Before going through the Zika diagnostic tests, I would like to 
make the point that there are no licensed Zika tests in the US.  
Rather, all currently available Zika tests – at CDC, health 
departments, and commercial labs – are being used under an 
FDA Emergency Use Authorization. This mechanism allows 
unlicensed tests to be used in a public health emergency.  
• Diagnostic testing for Zika virus infection can be accomplished 
using both molecular and serologic methods.  
• The molecular method - called RNA nucleic acid testing, also 
referred to as NAT, detects viral RNA in body fluids including 
serum and urine. rRT-PCR is a type of nucleic acid testing. 
Anytime Zika RNA is detected, Zika virus infection is confirmed.  
• The serologic tests, usually done through a simple blood draw, 
detect antibodies to Zika virus. This includes the Zika virus 
immunoglobulin M (IgM) assay to detect [anti-Zika virus] IgM 
antibodies in serum. 
• An additional serologic test is the plaque reduction 
neutralization test, or PRNT, which measures virus-specific 
neutralizing antibodies, and can be helpful to differentiate Zika 
from other flavivirus infections. 
 
 
• There are a number of limitations to keep in mind when 
interpreting both Zika molecular and serologic assays. First, 
since Zika virus RNA in serum and urine are short-lived, negative 
results do not preclude infection.  
• Second, testing for Zika virus IgM can result in false positive 
results because of significant cross-reactivity with other 
flaviviruses such as dengue and for other non-specific reasons. 
• Third, PRNT may not distinguish the type of infecting virus in 
people previously infected with or vaccinated against a related 
flavivirus. 
 
• Next, I will discuss CDC’s current guidance regarding Zika and 
pregnant women. 
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• CDC recommends Zika testing for all pregnant women with 
possible exposure to Zika virus and signs or symptoms of Zika 
virus infection.  
• In addition, pregnant women with possible exposure to Zika 
virus who do not report symptoms should also be tested. 
• Testing recommendations for asymptomatic pregnant women 
with possible Zika virus exposure differ based on the 
circumstances of possible exposure (i.e., ongoing versus limited 
exposure) and the elapsed interval since the last possible Zika 
virus exposure.   
 
 
• The specific testing plan for a pregnant woman depends on 
several factors, including whether she had symptoms of Zika and 
how much time has elapsed since her symptoms or last possible 
Zika exposure. This is described in the CDC guidance. 
o This flow chart was published in the updated pregnancy 
guidance in CDC’s Morbidity and Mortality Weekly Report 
on July 29, 2016. In the next few slides, I will briefly describe 
the updated guidance. 
 
 
• Symptomatic pregnant women evaluated within two weeks 
after symptom onset should receive Zika virus testing of their 
serum and urine using NAT testing. A positive result confirms a 
diagnosis of a recent Zika virus infection. A negative result does 
not rule out infection. Therefore if the NAT tests on both serum 
and urine are negative, then Zika virus IgM and dengue virus 
IgM antibody testing should be immediately performed. 
• If evaluated within 2-12 weeks after symptom onset, a pregnant 
woman should first have a Zika virus IgM test, and if the test is 
positive or equivocal, NAT should be performed on serum and 
urine. 
 
 
• For asymptomatic pregnant women who live in an area without 
Zika but who may have been exposed to Zika 
o If evaluated within 2 weeks after last possible exposure, NAT 
testing should be performed on serum and urine. If 
negative, Zika virus IgM testing should be performed 2-12 
weeks after exposure. 
o If evaluated 2-12 weeks after last possible exposure, Zika 
virus IgM testing should be performed. If positive or 
equivocal, NAT testing should be performed on serum and 
urine. 
• Asymptomatic pregnant women who live in an area with Zika 
should receive Zika virus IgM testing at the start of prenatal care 
and again during the 2nd trimester.   
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• For symptomatic and asymptomatic pregnant women with 
possible Zika virus exposure who seek care >12 weeks after 
symptom onset or possible exposure 
• IgM antibody testing might be considered 
o A negative IgM antibody test or NAT result >12 weeks after 
symptom onset or possible exposure does not rule out 
recent Zika virus infection because IgM antibody and viral 
RNA levels decline over time. 
• Given the limitations of testing beyond 12 weeks after symptom 
onset or possible exposure, serial fetal ultrasounds should be 
considered. 
 
• This tool is also available online at CDC.gov/Zika and provides 
information on the prenatal and postnatal management of 
pregnant women based on their laboratory test results. 
 
 
• Prenatal management is similar for pregnant women with 
confirmed recent Zika or flavivirus and presumptive recent Zika 
virus or flavivirus infection. 
• Clinical management includes serial fetal ultrasounds every 3-4 
weeks to assess fetal anatomy and monitor growth. 
Amniocentesis should be individualized for pregnant women 
with confirmed recent Zika virus or flavivirus infection and can 
be considered for pregnant women with presumptive recent 
Zika virus or flavivirus infection.  
 
 As I mentioned, Zika virus infection has serious potential health 
implications for pregnant women and their fetuses. Let’s 
continue to discuss how to prevent Zika virus infection.  
 
• First, CDC recommends that pregnant women not travel to areas 
with Zika.  
• If a pregnant woman must travel to an area with Zika, she 
should talk to her healthcare provider before departing and 
strictly follow steps to avoid mosquito bites and prevent sexual 
transmission during her trip. 
• Upon her return, she should talk to her healthcare provider, 
even if she doesn’t feel sick.  
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• All pregnant women should prevent mosquito bites by wearing 
long sleeved shirts and long pants.   
• Whenever possible, pregnant women should also stay and sleep 
in air-conditioned places or places that have window and door 
screens.   
• The use of insect repellants with EPA-registered ingredients is 
important. Insect repellents should contain one of the following 
active ingredients listed on this slide. When used as directed, 
these insect repellants are proven safe and effective, even for 
pregnant and breastfeeding women. 
• Finally, items that hold water such as tires, planters, and 
birdbaths should be emptied and scrubbed, turned over, 
covered, or thrown out once a week since mosquitoes lay eggs 
near water. 
 
• Pregnant women should also take actions to prevent Zika 
infection through sex.  
• If a pregnant woman’s partner lives in or has traveled to an area 
with Zika, healthcare providers should advise that the couple 
use condoms from start to finish every time they have sex or not 
have sex during the entire pregnancy. 
• It is important that these actions are taken for the duration of 
the pregnancy, even if the woman’s partner does not have 
symptoms or feel sick.    
 
 
• Next, we’ll switch gears again and discuss infection control in 
the healthcare setting through use of Standard Precautions in 
the context of Zika virus. 
 
• To date, there have been no reports of transmission of Zika virus 
from infected patients to healthcare personnel or other patients 
in healthcare settings. 
• Zika virus has been detected in blood, amniotic fluid, urine, 
saliva, and genital fluids (including semen and vaginal fluids), so 
standard infection prevention precautions are still necessary. 
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• Healthcare personnel must adhere to Standard Precautions in all 
healthcare settings. 
• This is already-existing guidance, but Zika provides an 
opportunity to emphasize the importance of following these 
existing protective recommendations.  
• Standard precautions are basic measures to prevent infection 
and are a group of practices that apply to all patients, regardless 
of suspected or confirmed infection status, in any setting in 
which healthcare is delivered.   
• The goals of implementing standard precautions are to  
o Prevent direct contact between a patient’s body fluids and 
the healthcare provider’s mucous membranes or broken 
skin 
o To protect healthcare providers and prevent them from 
transmitting potentially infectious material from one patient 
to another; 
o And to avoid percutaneous exposure to contaminated sharp 
implements. 
 
• One component of Standard Precautions is the use of personal 
protective equipment (or PPE), such as gloves, gowns, face 
masks, face shields, and goggles.  
• Facilities should assure that sufficient and appropriate PPE is 
available and readily accessible to healthcare personnel. In 
addition, healthcare personnel should be educated on the 
proper selection and correct use of PPE. 
• Examples of high-risk obstetric procedures that require 
increasing amounts of PPE in the labor and delivery setting 
include:  
o Vaginal examinations, particularly during amniotomy, when 
exposure to fluids would be expected;  
o Performing a vaginal delivery or manual removal of a 
placenta when exposure to larger volumes of fluids would 
be anticipated; and  
o Procedures in an operating room setting. 
 
• So, what is CDC doing to learn more about Zika and respond?  
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 Our understanding of Zika virus continues to evolve. Although 
we have learned about the association of Zika and poor 
pregnancy outcomes in a short amount of time, many questions 
remain. For example: 
o What is the level of risk from a Zika virus infection during 
pregnancy? 
o When during pregnancy does Zika virus infection poses the 
highest risk to the fetus? 
o What is the full range of potential health problems that Zika 
virus infection may cause? 
o What other factors (e.g., co-occurring infection, nutrition, 
symptomatic vs. asymptomatic) might affect the risk for 
birth defects? 
o What is the risk for later health problems in an infant who is 
infected or who has had exposure to Zika virus but is born 
without abnormalities? 
• Answering these critical questions is a focus of our ongoing 
research and ultimately may help reduce the effects of Zika 
infection during pregnancy and anticipate the needs of women 
infected with Zika virus during pregnancy, children with 
congenital Zika infections, and their families. 
 
 This slide lists some of what CDC is doing to learn more about 
Zika infection during pregnancy. 
o CDC established the US Zika Pregnancy Registry in 
collaboration with state, tribal, local, and territorial health 
departments in the United States and territories (excluding 
Puerto Rico). The registry collects information about women 
with laboratory evidence of possible Zika virus infection 
during pregnancy, whether or not they have symptoms, and 
their infants.  
o CDC helped develop a similar system in Puerto Rico, the Zika 
Active Pregnancy Surveillance System.  
o Additionally, enhanced surveillance of pregnant women 
with Zika in Colombia has been established. 
o CDC supports 45 jurisdictions in the US to conduct Zika-
related birth defects surveillance to better understand Zika 
exposure during pregnancy and adverse outcomes. 
o ArboNET, an existing national arboviral surveillance system 
managed by CDC and state and territorial health 
departments, collects information on laboratory-confirmed 
Zika virus disease cases reported from US states and 
territories. The data from this system will help us 
understand the effects of postnatal Zika infection. 
 Data will be used to update recommendations for clinical care, 
plan for services for pregnant women, their infants and families 
affected by Zika, and improve prevention of Zika infection 
during pregnancy. 
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 Every new finding from a published study, each new data point 
collected –all this information feeds into what is known about 
Zika and directs our public health action. CDC is rapidly 
translating new findings into messages for the public and 
updated clinical guidance, and is committed to sharing what we 
know when we know it. 
 CDC maintains a 24/7 Zika Pregnancy Hotline for healthcare 
providers of pregnant patients with possible Zika virus infection. 
Through this service, CDC scientists and clinicians are available 
for any concerns about clinical management and to answer 
questions about the US Zika Pregnancy Registry by telephone or 
email consultation. Providers and the general public can also ask 
questions through CDC INFO at 800-CDC-INFO (800-232-4636) or 
www.cdc.gov/cdc-info.  
 
 CDC has also developed a number of communication materials 
for healthcare providers and their patients.    
 These materials, available on the CDC website in a variety of 
languages, help translate CDC’s clinical guidance into tools for 
use in a clinical setting.  
 
 All of us, as healthcare professionals or members of the 
community, can work together to help improve our 
understanding of the effects of Zika and to improve awareness 
of how to prevent Zika.  
 
 Zika virus disease and Zika virus congenital infection are 
nationally notifiable conditions that should be reported to the 
National Notifiable Diseases Surveillance System (NNDSS). 
 The following cases should be reported to your state health 
department:  
o Symptomatic and asymptomatic cases with laboratory 
evidence of Zika virus infection  
o Infants born with or without abnormalities consistent with 
CZS and laboratory evidence of Zika virus infection 
 Reporting to the US Zika Pregnancy Registry, as described in 
next slide, is voluntary.   
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 As we discussed briefly, CDC established the US Zika Pregnancy 
Registry to monitor pregnancy and infant outcomes to help 
inform clinical guidance and direct public health action.  
 The registry casts a wider net than ArboNET and National 
Notifiable Diseases Surveillance System as it pertains to Zika, 
because the registry includes symptomatic and asymptomatic 
pregnant women with positive, equivocal, or inconclusive Zika 
test results with or without symptoms. It also includes all infants 
born to these women, not only those with identified congenital 
infection, and they will be followed for 1 year.  
 As a healthcare provider, you can support the registry by 
spreading the word about its importance, and working with your 
health department to report cases and collect clinical and 
follow-up information. 
 If you have clinical questions or questions about reporting to the 
pregnancy registry, you can go to the CDC website for 
information or contact CDC via email or phone. 
 
 To summarize, as a healthcare provider, here’s what you can do:  
o Know the basics about Zika transmission and prevention  
o Understand the assessment and management of Zika among 
pregnant women and protect them from exposure, 
o Counsel couples on Zika prevention if they are planning a 
pregnancy 
o Provide access to effective contraception for those not 
planning pregnancy, and  
o Inform your state or local health department and the US 
Zika Pregnancy Registry as indicated.  
 
 Additional information and resources can be found on the CDC 
website. 
 
 All of this is the work of many people. Many thanks to all of our 
collaborators, and thank you all for listening today. 
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Frequently Asked Questions 
 
What are the suggested timeframes for waiting to get pregnant after possible exposure to Zika? 
 Regardless of whether they have symptoms, men with possible Zika exposure who do not live in 
areas of active transmission but who are considering pregnancy with their partner should wait 
at least 6 months after last possible exposure (without symptoms) or symptom onset (with 
symptoms) before trying to conceive. 
 Women with possible Zika virus exposure who do not live in areas of active transmission but 
who are thinking about becoming pregnant should wait at least 8 weeks  after symptoms start 
or last possible exposure before trying to conceive; this recommendation remains unchanged 
from the previous guidance. 
 Women with possible Zika virus exposure who are not pregnant and do not plan to become 
pregnant and their male partners who want to minimize their risk of sexual transmission should 
use condoms in addition to their chosen birth control method, or they should not have sex for 
the same timeframes listed above. Correct and consistent use of condoms also reduces the risk 
for other sexually transmitted infections. 
 Women of reproductive age and their partners should use the most effective contraceptive 
methods that meet their lifestyle needs and can be used correctly and consistently.  
 
Where can I find information about areas with Zika? 
This information is available online at Areas with Zika  
 
How is Zika spread?  
 Zika virus is spread to people primarily through the bite of an infected Aedes species mosquito 
(Ae. aegypti and Ae. albopictus).  
 A pregnant woman can pass Zika virus to her fetus during pregnancy or around the time of birth. 
We do not know how often this happens.  
 A person with Zika virus can pass it to his or her sex partners.  
 Zika may be spread through blood transfusion.  
 One case of Zika has been confirmed in a person in Utah with no known risk factors; however, 
the person did provide care to another person who had very high amounts of Zika virus in his 
blood. Although the route of transmission is not certain, family contacts should be aware that 
blood and body fluids of severely ill patients might be infectious.  
 Transmission of Zika virus infection through breastfeeding has not been documented. 
 
How should pregnant patients who are considering travel to an area with active Zika virus 
transmission be counseled? 
CDC recommends that pregnant women not travel to an area with Zika. If a pregnant woman is 
considering travel to one of these areas, she should talk to her healthcare provider. If she travels, she 
should be counseled to strictly follow steps to avoid mosquito bites during the trip, and use condoms to 
 16 
 
reduce exposure to possible sexual transmission of the virus. If a pregnant woman has a partner who 
lives in or has traveled to an area with Zika, she should be counseled to either use condoms from start to 
finish every time she has sex, or not have sex (vaginal, anal, and oral sex, and sharing of sex toys) during 
her pregnancy to prevent sexual transmission. 
 
What types of testing for Zika virus are available to diagnose pregnant women? 
The type of testing recommended varies depending on the time of evaluation relative to symptom onset 
or last date of possible exposure. 
 Testing of serum and urine by RNA nucleic acid  testing (NAT; e.g., rRT-PCR) is recommended for 
pregnant women who seek care up to 2 weeks after symptom onset or last date of possible 
exposure. A positive NAT test confirms the diagnosis of recent maternal Zika virus infection. 
 For pregnant women who seek care 2-12 weeks after symptom onset or last date of possible 
exposure, serologic assays can be offered to detect Zika virus-specific IgM antibodies.  
 Immediate NAT testing is now recommended for women who have a positive or equivocal Zika 
virus IgM result, because it provides the potential for a definitive diagnosis of Zika virus 
infection. 
 Negative NAT results should be followed up with plaque reduction neutralization testing to 
measure virus specific neutralizing antibodies to confirm the presence of an immune response 
to a flavivirus infection and to differentiate Zika infection from other similar illnesses. 
Interpretation of serologic results has been described and published elsewhere. 
 
Does a positive Zika virus IgM always indicate Zika virus infection? 
No; a positive IgM result can be difficult to interpret since cross-reactivity can occur with related 
flaviviruses (e.g., dengue, Japanese encephalitis, West Nile, yellow fever). A positive Zika virus IgM result 
may reflect: previous vaccination against a flavivirus (e.g., yellow fever); previous infection with a 
related flavivirus; or recent or current infection with a flavivirus, including Zika virus. 
 
Is testing the semen of men with possible exposure to Zika virus recommended? 
No, testing the semen of men with possible exposure to Zika virus is not currently recommended. 
Testing of semen has not yet been validated and interpretation of the test results is not yet understood. 
Intermittent shedding in semen can occur with other viruses and the pattern of Zika virus shedding in 
semen is unknown. In addition, the detection of Zika virus RNA in semen might not indicate the 
presence of infectious virus in semen. Studies are underway to better understand the performance of 
these tests, the persistence of Zika virus in semen, and how best to interpret the results. 
 
What should providers consider when ordering a test for Zika virus infection? 
Each clinical scenario is unique, and healthcare providers should consider all available information when 
ordering a test for Zika virus infection, including patient travel history or possible exposure through 
sexual contact, history of flavivirus infection, vaccination history, ultrasound findings, and the presence 
of symptoms. Providers should work with their state, local, and territorial health departments for 
assistance obtaining and interpreting test results. 
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What should healthcare personnel do to avoid spreading Zika virus in healthcare settings?  
CDC released a report emphasizing the importance of healthcare personnel following practices, called 
Standard Precautions, to prevent the spread of infectious diseases such as Zika when caring for all 
patients, including pregnant patients in labor and delivery settings. Currently, there are no confirmed 
reports of Zika spreading from an infected patient to a healthcare provider or other patients. However, 
healthcare personnel are reminded to use Standard Precautions when they might come in contact with 
high volumes of body fluids. Standard Precautions to minimize contact with body fluids are important to 
reduce the possibility of spreading infectious diseases such as Zika.  
 
